TOP TIERMARKET NEWSWIRE
News & sentiment

UROGEN PHARMA LTD (URGN) — News & AI sentiment

UROGEN PHARMA LTD (URGN) news roundup. 2 stories in the past week, 15 over 30 days. Average 30-day sentiment is 56.6/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 5 sales totalling $3.7M — net selling of $3.7M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
2
avg sentiment 59.5/100
30d stories
15
avg sentiment 56.6/100
Insider net (90d)
$3.7M
0 buys · 5 sells
Congress (90d)
0
0 buys · 0 sells

URGN news in the last 24 hours, 7 days, 30 days and 90 days

How much URGN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowURGN storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days259.5/100URGN headlines →
Last 30 days1556.6/100URGN headlines →
Last 90 days3458.1/100URGN headlines →

Latest stories on URGN

Jefferies reiterates UroGen Pharma stock rating on rival drug data
Investing.com Analyst Ratings52 · neutralanalyst
3d ago
Urogen Pharma: Upside After Bladder Cancer Launch
Seeking Alpha67 · bullishproduct/pr
4d ago
Sep 4
Sep 4
Sep 2
Sep 2
Aug 21
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing
Investing.com Analyst Ratings56 · neutralanalyst
Aug 20
Aug 20
Aug 20
Aug 20
UroGen Pharma Ltd. (URGN) files 8-K
SEC 8-K50 · neutralgeneral
Aug 20
Aug 20
UroGen Pharma submits UGN-103 NDA to FDA
The Fly63 · neutralgeneral
Aug 17
Aug 17
UroGen (URGN) Q2 2026 Earnings Call Transcript
The Motley Fool71 · bullishearnings
Aug 12
Guggenheim raises UroGen Pharma stock price target to $58 on sales beat
Investing.com Analyst Ratings61 · neutralanalyst
Aug 6
Aug 5
Aug 5
Aug 5
Aug 5
Aug 5
UroGen Pharma Ltd. (URGN) files 8-K
SEC 8-K50 · neutralgeneral
Aug 5
Aug 5
UroGen Pharma Q2 2026 Earnings Preview
Seeking Alpha55 · neutralearnings
Aug 4
Open URGN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →